Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study

The glucagon-like peptide-1 receptor agonist (GLP-1RA) dulaglutide has been shown to improve body weight and glycemic control and reduce major cardiovascular (CV) events. In Japan, dulaglutide is used at a fixed dose of 0.75 mg, which is lower than that in Europe and North America. However, the repo...

Full description

Bibliographic Details
Main Authors: Hisayuki Katsuyama, Mariko Hakoshima, Shohei Umeyama, Sakura Iida, Hiroki Adachi, Hidekatsu Yanai
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Biomedicines
Subjects:
GLP-1 receptor agonist
dulaglutide
type 2 diabetes
Online Access:https://www.mdpi.com/2227-9059/11/3/869

Similar Items

Similar Items